Found 106 clinical trials
Minimal Invasive Axillary Staging and Treatment After Neoadjuvant Systemic Therapy in Node Positive Breast Cancer
Today, the majority of clinically node positive (cN+) breast cancer patients is treated with neoadjuvant systemic therapy (NST). Axillary staging and treatment after NST in cN+ patients are areas of controversy.
- 0 views
- 19 Feb, 2024
Clinical Study on Raman Spectra of Blood Saliva and Urine in Patients With Cancer Treated by Modern Therapy
Blood, saliva and urine samples of tumor patients on the day of admission and discharge were collected for Raman spectral analysis, which provided exploration for the prediction of efficacy, follow-up and prognosis according to the variation characteristics of Raman spectral.
- 0 views
- 19 Feb, 2024
Locoregional Surgery of the Primary Tumor in de Novo Stage IV Breast Cancer Patients
Current guidelines lack definitive evidences about the relative benefits of locoregional surgery for the primary tumor in de novo stage IV breast cancer. The aim of this study (SYSBTC-001) was to investigate the role of locoregional surgery for primary tumor in de novo stage IV breast cancer.
- 0 views
- 19 Feb, 2024
Glucose Monitoring During Chemotherapy
This is a research study to look at blood sugar changes during chemotherapy using a continuous blood sugar monitoring device. The device uses patches that attach to the skin on the back of the arm to measure blood sugar changes for the duration of the chemotherapy course. Each patch lasts …
- 0 views
- 19 Feb, 2024
Cancer Therapy Effects on the Heart
Anthracycline chemotherapies (e.g. doxorubicin, daunorubicin) is commonly given to treat pediatric cancer, and carries a risk of cardiotoxicity. Over the long term, children who receive these therapies have an increased risk of heart failure and early cardiovascular death. However, current strategies for identifying patients who are at risk prior to …
- 0 views
- 19 Feb, 2024
Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population
Introduction: Second Generation Antipsychotics (SGAs) are widely used in the pediatric population. It is currently established that SGAs may induce undesirable metabolic adverse events (AEs) such as weight gain, metabolic changes in blood lipids or glucose with risk of potential cardiovascular morbidity and mortality. The Canadian Alliance for Monitoring Effectiveness …
- 0 views
- 19 Feb, 2024